A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata

Inclusion criteria

• ✓. Male or female subject aged 18 to 55 years, inclusive, at the time of informed consent.
• ✓. Subject has a body mass index (BMI) between 18.0-35.0 kg/m2, inclusive, at screening.
• ✓. Subject has a body weight ≥ 50 kg, inclusive, at screening.
• ✓. Subject has a clinically confirmed diagnosis of AA at screening visit, based on investigator's judgement.
• ✓. For the treatment area(s) receiving ALD-102 Solution: subject must have AA lesion(s) that can accommodate the required number of injections per cohort: 20 injections for Cohorts 1#-3# and 40 injections for Cohort 4#.
• ✓. For the control area:
• ✓. Duration of current episode of hair loss at the treatment and control areas \> 6 months but \< 5 years at screening and Day 1, along with investigators' assessment that hair regrowth is possible. Total duration of current episode of hair loss outside of treatment and control areas and total duration since diagnosis of AA could be \> 5 years.
• ✓. No evidence of active regrowth or hair loss present at baseline and no known history of significant regrowth or hair loss, as per investigator's judgement, over the last 6 months.

Exclusion criteria